• 0.4% Trypan Blue Solution: Application in Cell Viability Ass

  2026-08-05

  0.4% Trypan Blue Solution offers a direct method for distinguishing viable from non-viable cells in biological research, enabling accurate cell counting and viability assessment. It should be deployed in laboratory workflows where clear live/dead cell discrimination is required, but is not suitable for diagnostic or clinical applications.

• BMS-777607: A c-Met Inhibitor for Optimized Platelet and Can

  2026-08-05

  BMS-777607 is redefining both hiPSC-derived platelet workflows and cancer metastasis modeling with its potent, selective c-Met inhibition. Learn how cutting-edge protocols and troubleshooting strategies empower advanced research, from cost-effective platelet production to robust signaling pathway interrogation.

• Fiber Density Modulates Collagen Heterogeneity in Annulus Fi

  2026-08-04

  This study identifies scaffold fiber density as a decisive mechanobiological regulator of collagen heterogeneity in the annulus fibrosus (AF). By leveraging differential mechanotransduction pathways, the research provides a blueprint for engineering spatially organized scaffolds that better recapitulate the native structure and function of intervertebral disc tissue.

• Selective IRAP Inhibitors via α-Hydroxy-β-Amino Acid Bestati

  2026-08-04

  This study presents a stereoselective synthetic route to α-hydroxy-β-amino acid derivatives of bestatin, yielding the first cell-active, nanomolar inhibitors highly selective for insulin-regulated aminopeptidase (IRAP). High-resolution crystallography reveals key structural determinants for selectivity and potency, establishing a foundation for future therapeutic exploration targeting M1 zinc aminopeptidases.

• ECL Western Blotting Substrate: Technical Guidance & Workflo

  2026-08-03

  ECL Western Blotting Substrate (SKU K2187) is designed for sensitive chemiluminescent detection of horseradish peroxidase in Western blot assays, providing clear signal intensity without the hazards of radioisotopic reagents. It is not suitable for fluorescent or radioisotopic workflows and is optimized for rapid, reproducible protein detection in molecular and cancer biology research.

• Generation of Hepatobiliary Organoids from hiPSCs: A Technic

  2026-08-03

  This study demonstrates the first successful in vitro generation of functional hepatobiliary organoids from human induced pluripotent stem cells (hiPSCs) without genetic modification or exogenous cells. The organoids closely recapitulate key hepatic and biliary functions, offering a robust platform for studying liver development and disease modeling.

• L-NMMA Acetate: Advanced NOS Pathway Modulation in Research

  2026-08-02

  L-NMMA acetate empowers researchers with precise inhibition of all three NOS isoforms, unlocking nuanced exploration of nitric oxide signaling in inflammation and regenerative medicine. Discover practical protocol enhancements and troubleshooting insights that maximize reproducibility and data quality.

• Annexin V-FITC/PI Apoptosis Assay Kit: Technical Guide

  2026-08-01

  The Annexin V-FITC/PI Apoptosis Assay Kit allows researchers to rapidly distinguish between viable, apoptotic, and necrotic cells using a dual-fluorescence protocol compatible with flow cytometry and fluorescence microscopy. It is well suited for research applications in cell death analysis but is not intended for diagnostic or medical use.

• EZ Cap™ Mouse IL-12 mRNA (m1Ψ): Data-Driven Workflow Solutio

  2026-07-31

  This article provides a scenario-based, evidence-backed guide for researchers using EZ Cap™ Mouse IL-12 mRNA (m1Ψ) (SKU R1058) in immune activation, cell viability, and gene expression studies. It addresses common laboratory challenges such as reproducibility, immunogenicity, and delivery optimization, offering practical insights and protocol parameters rooted in recent advances and peer-reviewed findings.

• DOT1L Inhibition Enhances Lenalidomide Response in Myeloma

  2026-07-31

  The referenced study reveals that inhibiting DOT1L, a histone methyltransferase, reprograms innate immunity in multiple myeloma (MM) cells, markedly enhancing the efficacy of immunomodulatory drugs such as lenalidomide. These results provide mechanistic insight into the synergy between epigenetic modulation and immune activation, supporting new combination approaches for MM research.

• METTL17 Links Mitochondrial Translation to Ferroptosis in CR

  2026-07-30

  This study uncovers the mitochondrial protein METTL17 as a key regulator of ferroptosis resistance in colorectal cancer (CRC) by modulating mitochondrial RNA methylation and translation. The findings reveal a novel mitochondrial defense mechanism and identify METTL17 as a potential therapeutic target for sensitizing CRC cells to ferroptosis-based therapies.

• Dissecting Drug Response Metrics: Insights from In Vitro Can

  2026-07-30

  Schwartz's dissertation critically evaluates how distinct in vitro metrics—relative viability and fractional viability—capture different facets of anticancer drug responses. This work clarifies that drug-induced growth inhibition and cell death are often conflated but mechanistically distinct, providing essential guidance for researchers interpreting cytotoxicity assays and optimizing experimental design.

• Sequencing Therapies in Waldenström Macroglobulinemia: CXCR4

  2026-07-29

  This article reviews the pivotal role of genomic profiling—especially MYD88 and CXCR4 mutations—in guiding therapy selection and sequencing for Waldenström Macroglobulinemia (WM), as detailed in the referenced 2021 review. The findings underscore how emerging targeted agents, such as CXCR4 antagonists, are reshaping the management of challenging WM subgroups and highlight the need for individualized, mutation-driven treatment strategies.

• Fucoidan Downregulates Caveolin-1 in MCF-7 Breast Cancer Cel

  2026-07-29

  This study reveals that fucoidan, a sulfated polysaccharide from brown algae, selectively suppresses caveolin-1 expression and impedes proliferation and migration in MCF-7 breast cancer cells. The findings highlight caveolin-1 modulation as a novel and promising target for breast cancer therapy, with implications for both natural product research and combinatorial treatment strategies.

• Predicting Major Bleeding During Extended Anticoagulation fo

  2026-07-28

  This study introduces and validates a novel clinical prediction model (CHAP) for major bleeding risk during extended anticoagulation in patients with unprovoked or weakly provoked venous thromboembolism (VTE). By comparing the CHAP model with existing risk scores, the research provides a more streamlined approach to risk estimation, potentially informing safer anticoagulation management.

15761 records 1/1051 page Next 12345 下5页 Last page